Our Portfolio
At a glance
Meet the teams currently transforming academic research into transformative new drugs.
Our portfolio combines deep expertise with exceptional scientific potential. We partner with world-class scientists to rapidly advance pioneering programmes, accelerating high-potential breakthroughs towards drug development.
SSTX—002 | SSTX—003
ALTx Therapeutics
Multiple small molecule therapeutics for treatment of cancers that use of the ALT pathway.
SSTX—001
Apini Therapeutics
Novel small molecule therapeutics for the treatment of inflammatory diseases without induction of immune suppression.
Want to be the
next programme in
Slingshot’s portfolio?
Perspectives
that matter
Dr Sam Butterworth
Apini Therapeutics, Founder
Being a part of Slingshot has absolutely transformed Apini. The ability to lean on such an expert network who really push you to make your idea the best it possibly can be, is just priceless.
Kate Butler
Director
New assets often lack the robust financial foundation and well-defined structures they so desperately need in the early days; Slingshot provides this effortlessly whilst also driving clinical progress forward at the same time.
Andrew Wilkinson
UoM Innovation Hub, CEO
Having strong connections with biotech accelerators is crucial for the success of the programmes in our Innovation Hub; and there’s no better example of their value than Slingshot.